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Background:Tuberculous pericarditis includes the spectrum of pericarditis caused by 
Mycobacterium tuberculosis manifesting with pericardial effusion, cardiac tamponade, 
effusive-constrictive and constrictive pericarditis. In patients with pericardial tuberculosis, 
co-infection with human immunodeficiency virus (HIV) is associated with increased 
incidence of haemodynamic instability, electrocardiographic (ECG) ST elevation and 
mortality, suggesting an aggressive myopericarditis. However, little is known about 
myocardial involvement in patients with pericardial tuberculosis. Cardiovascular magnetic 
resonance (CMR) can assess non-invasively cardiac function, myocardial oedema, 
inflammation and fibrosis.  
Objectives: To assess cardiac and pericardial structure and function in patients with TBPC 
with and without HIV co-infection and to assess the relationship of left ventricular (LV) 
function with other imaging biomarkers. 
Methods: 72 patients with TBPC (37 male (51.3%), mean age 40 ± 14.3) were included in the 
study.   Of these, 35 were HIV infected (17 male (48.6%), mean age 34 ± 8) and 37 were 
HIV uninfected (20 male (54.1%), mean age 51 ± 16). Assessments included clinical 
examination, ECG, echocardiography, serum and pericardial biomarkers and CMR 
(biventricular volumes and function, oedema, and late gadolinium enhancement - LGE). 
Results: HIV infected TBPC patients were younger (p<0.001), had lower serum haemoglobin 
(p<0.001) and were more likely to have NYHA class III and IV symptoms (p<0.001). There 
were no differences on ECG and echocardiography between HIV infected and uninfected 
TBPC patients. There were also no differences in global systolic function between HIV 
infected and uninfected TBP patients. Focal fibrosis on LGE was found more commonly in 
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those with HIV infection (p<0.001). Pericardial effusions were frequent (>50%) in both 
groups of TBPC patients. Determinants of LV ejection fraction in TBPC included heart rate, 
LV size, E/A ratio, pericardial LGE and pericardial thickness (all p<0.01).  
Conclusions: HIV co-infection is associated with increased focal myocardial fibrosis in 
TBPC patients suggesting increased myocardial inflammation in those with HIV co-infection. 
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AIDS Acquired immunodeficiency syndrome 
ART Antiretroviral therapy 
CMR Cardiovascular magnetic resonance 
CVD Cardiovascular disease 
ECG Electrocardiography 
ECP Effusive-constrictive pericarditis 
HIV Human immunodeficiency virus 
LA Left atrium 
LBBB Left bundle brunch block 
LGE Late gadolinium enhancement 
LV Left ventricle/ventricular 
SI Signal intensity 
SSFP Steady state free precession 
SSA Sub-Saharan Africa 







In 2013, 9 million people developed tuberculosis and 1.5 million people died in the same year 
from tuberculosis, 360,000 of whom were HIV infected.1 Globally, the incidence of 
tuberculosis is declining each year, but continues to increase in many parts of the world, 
including sub-Saharan Africa (SSA).2 Tuberculosis has a complex interaction with the human 
immunodeficiency virus (HIV) infection, occurring at a multiplicity of levels.3Tuberculous 
pericarditis, caused by Mycobacterium tuberculosis,  is the most common cause of a large 
pericardial effusion in the developing world, accounting for 69.5% of effusions in a case 
series from the Western Cape, South Africa;4 and has a high mortality related to pericardial 
tamponade, constrictive pericarditis, arrhythmias and heart failure.5 
 
Cardiovascular manifestations of tuberculosis include pericarditis with pericardial effusion, 
cardiac tamponade, effusive-constrictive and constrictive pericarditis, calcific pericardial 
constriction, tuberculomas and vasculitis.6,7There has been a dramatic resurgence in 
tuberculous pericarditis in the context of co-infection with HIV. Over 90% of pericardial 
effusions in those infected with HIV in SSA are due to tuberculosis, compared with 50–70% 
in those without HIV and less than 5% in industrialised nations.8 
 
In patients with tuberculous pericarditis, co-infection with HIV is associated with increased 
incidence of haemodynamic instability, electrocardiographic (ECG) ST elevation and 
mortality, suggesting an aggressive myopericarditis in the context of HIV co-infection.9 
However, little is known about myocardial involvement in patients with tuberculous 




TBPC is a serious complication of tuberculous pericarditis, occurring in 30 to 60% of 
patients, despite prompt and adequate antituberculous treatment and steroids,10and is 
associated with high mortality.5 The mortality from TBPC is reduced by the use of 
corticosteroids in those without HIV infection.11,12 Tuberculosis remains the commonest 
cause of pericardial constriction in SSA.13 In SSA, many patients with TBPC present with a 
subacute variety of effusive-constrictive pericarditis (ECP), characterised by a thick, 
fibrinous exudate in the pericardial sac.14The diagnosis of ECP is considered probable if it is 
established on the basis of echocardiography or cardiovascular magnetic resonance (CMR). 
Currently, there are no published prospectively-derived consensus diagnostic criteria for ECP 
using these imaging modalities, but widely accepted criteria include presence of the 
following: (1) pericardial thickening; (2) abnormal or paradoxical motion of the 
interventricular septum; (3) a dilated inferior vena cava with reduced respiratory variation; 
and (4) marked respiratory variation of the mitral (and tricuspid) inflow Doppler patterns.15 
 
CMR can assess non-invasively cardiac function, myocardial oedema, inflammation and 
fibrosis.16To date, there have been no systematic, prospective CMR studies of tuberculous 
pericarditis. Smith and colleagues published the first case report of TBPC confirmed on CMR 
in 2001.17Russell et al demonstrated the role of CMR in characterising tuberculous ECP and 
how the CMR findings correlated with invasive haemodynamics.18 Further, our group has 
also demonstrated the role of CMR in monitoring of nodular myocardial tuberculosis 
following antituberculous therapy.19 Similarly, Grigoratoset al published a case report 
showing CMR evidence of focal oedema and late gadolinium enhancement (LGE), which 
resolved following antituberculous therapy.20 A single centre retrospective study of 11 
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Moroccan patients with pericardial constriction (only 4 of whom were suspected to be 
tuberculous) found LGE in 3 of 11 patients.21 
We hypothesised that HIV co-infection would be associated with increased myocardial 
pathology on CMR in patients with TBPC. Therefore, our study objectives were (1) to assess 
myocardial and pericardial structure and function in patients with TBPC with and without 
HIV co-infection, and (2) to assess the relationship of left ventricular (LV) function with 








The study subjects consisted of a prospectively acquired South African cohort, from the 
Western Cape Province, that were referred for investigation of tuberculous pericardial 
constriction at Groote Schuur Hospital between 2006 and 2014. In this study, we included 
those who underwent imaging with CMR (n=72). Patients were included into the study 
regardless of HIV-infection status. Patients with non-sinus rhythm were excluded from the 
study. All subjects gave written informed consent to participate in the study. Ethical approval 
was granted for all study procedures by the University of Cape Town Human Research Ethics 
Committee and all participants gave informed consent to participate in the study.  
 
Study metadata 
Patient demographics, including age, sex, weight and height were obtained from the patients’ 
clinic folders. Information such as patients’ history and symptoms were also obtained from 
the clinic folders and documented as dyspnea, paroxysmal nocturnal dyspnea, orthopnea, 
oedema, chest pain, palpitations, syncope, night sweats, fever, loss of weight, cough, and 
previous pulmonary tuberculosis. Past medical history was documented in detail, as were co-
morbid conditions. Investigations included electrocardiography (ECG), echocardiography, 






CMR studies were performed using a single 1.5 T MR system (Symphony, Siemens 
Healthcare, Germany). A 20-channel phased-array chest coil was used for all data 
acquisition, except for STIR imaging, for which the body coil was used. A complete stack of 
short axis images were obtained during breath hold and cardiac gating for cine,T2-weighted 
and LGE imaging. T2 weighted-CMR was performed with the black blood short-Tau 
inversion recovery (STIR) sequence, before administration of contrast agent. LGE imaging 
was performed using a T1-weighted phase-sensitive inversion recovery sequence about 6 
minutes after intravenous administration of contrast agent (Omniscan; 0.15 mmol/kg body 
weight).  
 
CMR image analysis 
All CMR images were analysed offline in a blinded fashion.  
Cine images  
Analysis of left ventricular ejection fraction was performed using Argus software (Siemens 
Medical Solutions, Erlangen, Germany). Left ventricular (LV) short axis epicardial and 
endocardial borders were manually contoured at end-diastole and end-systole. LV end 
systolic (LVESV) and end diastolic (LVEDV) volumes were used to calculate stroke volume 
(SV) and ejection fraction (EF) – (EF = SV/EDV). Myocardial mass was also calculated by 
subtracting the endocardial volume from the epicardial volume, based on prior knowledge of 




STIR images  
Quantitative analysis was performed by comparing the LV myocardium in short axis against 
adjacent skeletal muscle in the same slice, verified on a corresponding balanced steady state 
free precession (SSFP) image. The T2 signal intensity (SI) ratio was defined as 
SImyocardium/SIremote skeletal muscle. Myocardial oedema was diagnosed when myocardial T2 SI 
ratio is > 1.9. Care was taken to exclude non-suppressed blood pool signal due to slow flow 
adjacent to the subendocardium and to avoid using areas with abnormally low signal for 
normalisation.  
LGE images  
Images were evaluated qualitatively for the presence or absence, pattern (subendocardial, 
midwall, subepicardial, transmural) and regional distribution of LGE areas by two observers, 
each with at least 5 years of CMR experience. The detection of LGE was made by consensus 
of both observers.  
 
Statistical considerations 
Normality of data was tested using the Kolmogorov-Smirnov test. Normally distributed data 
are presented as mean ± standard deviation (SD) or, where highly skewed, as median 
(interquartile range); non-parametric data are presented as numbers (percentages). The chi-
square test or the Mann-Whitney U test was utilized for non-parametric data. Unpaired 
samples between groups were assessed by the unpaired 2-tailed Student t test. Correlation 
was assessed using the Pearson “R” and Spearman “RS” coefficient, as appropriate. All 
statistical tests were two-tailed, with p-values of less than 0.05 considered statistically 
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Of 72 patients included in the study, there was an almost even split between males (51.3%) 
and females (48.7%) with TBPC (Tables 1 and 2). Of the study population, 35 participants 
were HIV infected, with only 6 (17%) of these receiving combination antiretroviral therapy 
(ART). None of the HIV infected persons on ART were on a protease inhibitor.The median 
CD4 count was 165 (IQR 29-268). The mean age of the total study population was 40 ± 14 
years; however the HIV infected patients were younger with an average age 34 ± 8 years 
(p<0.001). There were no significant differences between HIV infected and uninfected 
persons when comparing body mass index, systolic and diastolic blood pressure and heart 
rate. Importantly, the prevalence of cardiovascular risk factors and comorbidities were low in 
this cohort.  
Table 1: Demographic details (N=72) 
Age, years 40.0 ± 14.3 
Male sex, n (%) 37 (51.3) 
BMI, kg/m2 22.9 ± 5.5 
Systolic BP, mmHg 110.4 ± 19.2 
Diastolic BP, mmHg 70.7 ± 11.6 
Heart rate, bpm 115.1 ± 22.3 
HIV infected, n (%) 35 (48.6) 
Receiving ART, n (%) 6 (8.3) 
On diuretic therapy, n (%) 9 (12.5) 
Continuous data are mean ± SD unless otherwise indicated 




Table 2. Demographic characteristics separated by HIV infection status 
 
 HIV infected (N=35) HIV uninfected (N=37) P value 
Age, years 33.7 ± 7.8 51.4 ± 15.8 <0.001 
Male sex, n (%) 17 (48.6) 20 (54.1) 0.46 
BMI, kg/m2 22.2 ± 4.8 23.8 ± 8.2 0.59 
SBP, mmHg 110.0 ± 20.2 111.5 ± 20.9 0.83 
Diastolic BP, mmHg 70.8 ± 9.6 71.2 ± 17.05 0.95 
Heart rate, bpm 116.2 ± 20.1 112.3 ± 22.6 0.57 
Receiving ART, n (%) 6 (17.1) 0 (0) − 
On diuretic therapy, n (%) 5 (14.3) 4 (10.8) 0.13 
Continuous data are mean ± SD unless otherwise indicated 
ART, antiretroviral therapy; BMI, body mass index; BP, blood pressure 
 
 
Dyspnoea was present in 83% and 41% in HIV infected and uninfected persons, respectively 
(p<0.001) − Table 3, in keeping with prior reports of greater degrees of dyspnoea in HIV-
infected persons.22,23 Interestingly, palpitations were more frequently reported in those with 
HIV infection (p=0.03). Constitutional features including cough (p=0.03), fever (p=0.04), 
weight loss (p=0.01) and night sweats (p=0.003) were more prevalent in those infected with 
HIV.  
 
Smoking was more prevalent in those who were HIV infected (p=0.007) – Table 4. Previous 
pulmonary tuberculosis was evident in the history of 11% and 11%, respectively, in HIV 
infected and uninfected persons (p=0.001).  
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Table 3. Clinical features 
 HIV infected (N=35) HIV uninfected (N=37) P value 
Dyspnea, n (%) 29 (82.9) 15 (40.5) 0.004 
NYHA FC, n (%) 
     NYHA I 
     NYHA II 
     NYHA III 












Orthopnea, n (%) 8 (22.9) 4 (10.8) 0.04 
PND, n (%) 5 (14.3) 2 (5.4) 0.08 
Palpitations, n (%) 6 (17.1) 2 (5.4) 0.03 
Syncope, n (%) 1 (2.9) 0 (0) − 
Pedal oedema, n (%) 8 (22.9) 6 (16.2) 0.64 
Cough, n (%) 29 (82.9) 11 (29.7) 0.03 
Fever, n (%) 11 (31.4) 7 (18.9) 0.04 
Night sweats, n (%) 18 (51.4) 7 (18.9) 0.003 
Loss of weight, n (%) 16 (45.7) 9 (24.3) 0.01 
Known TB contact, n (%) 2 (5.7) 1 (2.7) 0.55 
Continuous data are mean ± SD unless otherwise indicated 





Table 4. Comorbid cardiovascular risk factors 
 
 HIV infected (N=35) HIV uninfected (N=37) P value 
Smoking, n (%) 10 (28.6) 3 (8.1) 0.007 
Hypertension, n (%) 1 (2.9) 1 (2.7) 0.70 
Diabetes, n (%) 1 (2.9) 0 (0) − 
Dyslipidaemia, n (%) 0 (0) 0 (0) − 
COPD, n (%) 1 (2.9) 0 (0) − 
Previous PTB, n (%) 4 (11.4) 4 (10.8) 0.88 
Alcohol use, n (%) 3 (8.6) 1 (2.7) 0.26 
Continuous data are mean ± SD unless otherwise indicated 
COPD, chronic obstructive pulmonary disease; PTB, pulmonary tuberculosis 
 
 
Electrocardiographic and echocardiographic findings 
There were no significant differences on ECG between TBPC patients with and without HIV 
infection (Table 5). Of note, on echocardiography, there were also no significant differences 
between the two groups (Table 6). Trivial to mild atrioventricular valve incompetence was 
reported in a third of patients, overall. Echocardiographic evidence of tamponade was not 
seen in this cohort. Most patients had a diagnosis of ECP. Pericardial effusion was a present 





Table 5. Electrocardiographic features (N=48) 
 





Heart rate, bpm 108.1 ± 28.4 109.0 ± 26.6 0.96 
Rhythm 
     Sinus rhythm 
     Atrial fibrillation 










QRS axis, degrees 56.6 ± 35 58.4 ±28.3 0.89 
PR interval, ms 147.2 ± 25.3 135.3 ± 20.5 0.17 
PR elevation, n (%) 7 (20.6) 1 (7.1) 0.16 
Pathological Q waves, n (%) 1 (2.9) 0 (0) − 
QRS duration, ms 78.3 ± 12.1 75.9 ± 10.4 0.68 
ST elevation, n (%) 3 (8.8) 0 (0) − 
ST depression, n (%) 2 (5.8) 0 (0) − 
Repolarisation abnormalities, n 
(%) 
10 (29.4) 5 (35.7) 0.46 
QT interval, ms 422.3 ± 34.5 403.1 0.23 
Poor R wave progression, n (%) 7 (20.6) 3 (21.4) 0.66 
Microvoltage, n (%) 4 (11.8) 5 (35.7) 0.06 
Electrical alternans, n (%) 22 (64.7) 10 (71.4) 0.25 
Left ventricular hypertrophy, n 
(%) 
1 (2.9) 1 (7.1) 0.43 
Dominant R in V1, n (%) 1 (2.9) 0 (0) − 
Continuous data are mean ± SD unless otherwise indicated 
 
 30 
Table 6. Echocardiographic features (N=48) 
 
 HIV infected (N=34) HIV uninfected (N=14) P value 
LVIDd, cm 4.8 ± 0.6 4.2 ± 0.9 0.09 
LVIDs, cm 3.3 ± 0.7 3.2 ± 0.5 0.57 
Dilated LV24, n (%) 2 (5.9) 0 0.36 
IVSd, cm 1.0 ± 0.2 1.2 ± 0.4 0.26 
RV diameter, cm 2.3 ± 0.5 2.4 ± 0.2 0.89 
LV wall motion abnormality 
(septal bounce), n (%) 
3 (8.8) 4 (28.6) 0.12 
E/A 1.5 ± 1.0 1.7 ± 0.7 0.71 
LVEF, % 55.4 ± 17.1 47.8 ± 9.8 0.18 
FS, % 29.8 ± 10.2 25.0 ± 8.8 0.24 
PAP, mmHg 19.6 ± 10.0 16.4 ± 3.3 0.47 
MR, n (%) 10 (29.4) 4 (28.6) 0.54 
AR, n (%) 1 (2.9) 1 (7.1) 0.53 
TR, n (%) 8 (23.5) 3 (21.4) 0.69 
PR, n (%) 1 (2.9) 1 (7.1) 0.17 
LA dimension, cm 3.1 ± 0.6 3.3 ± 0.5 0.36 
RV/RA collapse, n (%) 3 (8.8) 2 (14.3) 0.62 
Respiratory variation, n (%) 8 (23.5) 4 (28.6) 0.62 
Dilated IVC, n (%) 3 (8.8) 2 (14.3) 0.53 
Increased pericardial thickness, 
n (%) 
9 (26.5) 7 (50.0) 0.11 
Pericardial effusion, n (%) 26 (76.5) 13 (92.9) 0.41 
Continuous data are mean ± SD unless otherwise indicated 
AR, aortic regurgitation; IVC, inferior vena cava; IVSd, interventricularseptal thickness in 
diastole; LA, left atrium; LV, left ventricle; LVEF, left ventricular ejection fraction; LVIDd, 
left ventricular internal dimension in diastole on echocardiography; LVIDs, left ventricular 
internal dimension in systole on echocardiography; MR, mitral regurgitation; PAP, 




Of the laboratory data, only the haemoglobin was found to be significantly lower in the HIV 
infected subjects (9.7g/dl vs. 12.7g/dl, p<0.001) – Table 7. Mycobacterium tuberculosis was 
cultured in 28.6% and 33.3% in the HIV infected and uninfected groups, respectively 
(p=0.57). Pericardial fluid adenosine deaminase (ADA) was found to be a sensitive marker 
for tuberculous pericarditis with mean values of 73 ± 23 and 99 ± 57 mmol/L in those with 
and without HIV infection, respectively (p=0.08). Positive Light’s criteria on pericardial fluid 
were highly sensitive for the diagnosis of tuberculous pericarditis, and were positive in 97% 
and 100% of HIV infected and uninfected participants who underwent pericardiocentesis, 
respectively (p=0.92). In our study, 16 patients had a cardiac Troponin T and creatinine 
kinase (CK-MB) performed and all these biomarker results were within normal limits, ruling 
out active myocardial injury in the patients studied.  
Cardiovascular magnetic resonance 
On CMR, there were no differences between the HIV infected and uninfected patients when 
comparing LV chamber size, stroke volume, global ejection fraction and LV mass index 
(Table 8); also there were no differences in left atrial size (all p values >0.05). While the T2-
weighted signal intensity ratios were higher in HIV infected patients (1.70 ± 0.21 vs. 1.49 ± 
0.20 %), these were within the normal range and did not reach statistical significance 
(p=0.19). The presence of LGE was significantly higher in HIVinfected persons with TBPC 
(71% vs. 22%, p<0.001). Pericardial thickening (0.5 ± 0.2 vs. 0.7 ± 0.3 cm, p=0.16), 
frequency of pericardial effusions (67 vs. 52%, p=0.19) and pericardial LGE (31% vs. 22%, 
p=0.11) was similar in HIV infected and uninfected patients, respectively.
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Table 7. Laboratory measurements 





Haemoglobin, g/dL 9.7 ± 2.0 12.7 ± 1.7 <0.001 
Creatinine, µmol/L 62.2 ± 16.9 88.9 ± 32.7 0.01 
Sputum gene Xpert, n (%) 0 0 − 
TB culture in PE, n (%) 10 (28.6) 5 (33.3) 0.57 
TB culture Other, n (%) 1 (2.9) 0 (0) − 
AFB positive in PE, n (%) 0 (0) 2 (13.3) − 
AFB positive in another site, n (%) 1 (2.9) 0 (0) − 
PE ADA, mmol 73.3 ± 23.3 98.9 ± 57.2 0.08 
PE protein, IU/L 64.3 ± 9.6 57.4 ± 7.9 0.04 





Serum protein, IU/L 80.2 ± 9.1 77.6 ± 6.6 0.36 
Serum LDH, IU/L 817.4 (410.4-1214.6) 536.6 (243.8-799.6) 0.05 
Positive Light’s criteria, n (%) 34 (97.1) 15 (100.0) 0.92 
Continuous data are mean ± SD unless otherwise indicated 
ADA, adenosine deaminase; AFB, acid fast bacilli; LDH, lactate dehydrogenase; PE, 





Table 8. Cardiovascular magnetic resonance findings 
 
 HIV infected (N=35) HIV uninfected (N=37) P value 
LVEDV, mL 143.7 ± 27.5 142.6 ± 26.3 0.90 
LVESV, mL 43.34 ± 22.4 36.5 ± 7.4 0.29 
LVSV, mL 100.4 ± 23.4 108.3 ± 22.4 0.31 
LVEF, % 63.86 ± 18.8 57.54 ± 22.1 0.33 
LVMI, g/m2 58.3 ± 14.3 56.7 ± 30.7 0.82 
LA size, cm 2.7 ± 0.5 2.8 ± 0.7 0.40 
Presence of LGE, n (%) 25 (71.4) 8 (21.6) <0.001 
Pericardial LGE, n (%) 11 (31.4) 8 (21.6) 0.11 
Myocardial T2 SI ratio, % 1.70 ± 0.21 1.49 ± 0.20 0.19 
Pericardial thickness, cm 0.5 ± 0.2 0.7 ± 0.3 0.16 
Pericardial effusion, n (%) 24 (68.6) 19 (51.4) 0.19 
Continuous data are mean ± SD unless otherwise indicated 
LA, left atrium; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular 
ejection fraction; LVESV, left ventricular end-systolic volume; LVMI, left ventricular mass 
indexed to body surface area; LGE, late gadolinium enhancement; SI, signal intensity 
 
Finally, while global LV systolic function was preserved overall in patients with TBPC in 
this study, there was also great variability in LVEF observed. We undertook Cox proportional 
hazard univariate regression analysis to investigate the determinants of LV function in this 
group of patients. Determinants of LV systolic function in TBPC included heart rate, LV size, 
E/A ratio, pericardial LGE and pericardial thickness (all p<0.01) – Table 9. 
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Table 9. Univariate regression analysis for predictors of LV function in TBPC 
 
Co-variates Pearson correlation (R) P value 
Heart rate -0,464 0.003 
LVIDd -0,711 <0.001 
E/A -0,572 <0.001 
Myocardial LGE -0,239 0.22 
Pericardial LGE -0,645 <0.001 




In this study, we used CMR to assess the myocardial phenotype of TBPC patients and we 
have found evidence of increased myocardial fibrosis in patients with HIV. Further, there was 
increased pericardial thickness with associated pericardial enhancement on LGE CMR, likely 
indicating pericardial fibrosis. Forty nine percent of study subjects were co-infected with 
HIV, with a median CD4 count of 165 mm3 and only 17% of these on ART. Of note, HIV 
infected TBPC patients were younger, had lower serum haemoglobin and were more likely to 
have NYHA class III and IV symptoms. Determinants of LV systolic function in TBPC on 
univariate analysis included heart rate, LV size, E/A ratio, pericardial LGE and pericardial 
thickness. These results have implications for the management of TBPC patients with HIV 
co-infection: the presence of increased focal myocardial fibrosis in patients infected with 
HIV may explain some of the higher mortality in this group of patients. In the future, it will 
be important to investigate therapeutic strategies that may improve prognosis of TBPC 
patients with dual infection. 
A previous CMR study on 90 treated HIV infected patients found that asymptomatic HIV 
infected persons had 47% higher median myocardial lipid content and 74% higher median 
plasma triglycerides. Further, focal mid-wall myocardial fibrosis was found in 76% of HIV 
infected persons compared to only 13% on HIV uninfected controls. These myocardial 
changes in HIV infected persons were associated with impairments in both systolic and 
diastolic strain and strain rates25 Moreover, these findings have been confirmed by a more 
recent publication.26In this study, we found that 71% of HIV infected participants had focal 
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myocardial fibrosis on LGE CMR compared to only 22% of HIV uninfected TBPC patients. 
While we hadhypothesised that patients co-infected with tuberculosis and HIV would have 
greater myocardial fibrosis, we are unable to assess the contribution of tuberculosis in driving 
myocardial fibrosis, as the frequency of fibrotic lesions can be explained by the HIV 
infection alone. The presence of myocardial fibrosis in patients with HIV infection may 
indicate prior myocardial inflammation/myocarditis.25 In the future, a study comparing HIV 
patients with and without TBPC will be important for addressing the issue of the contribution 
of tuberculosis. 
The vast majority of patients studied had small (sub-centimeter) pericardial effusions, in 
keeping with tuberculous ECP. While these effusions were more common in those with HIV-
infection, this difference did not reach statistical significance. Also, there was no difference 
in the size of the pericardial effusions when comparing HIV infected and uninfected patients. 
ECP is a clinical syndrome in which compressive pericardial fluid and a constricting visceral 
pericardium occur simultaneously.27 
The inflammatory process seen intuberculouseffusive pericarditis is distinct from that seen in 
patients with ECP.28Previous publications have reported that tuberculousECP is associated 
with higher levels of pericardial IL-10 and IFN-γ when compared to effusive non-constrictive 
disease.28 Similarly, the fibrotic and regulatory cytokine TGF-β is significantly elevated in 
the serum of tuberculous ECP patients. These findings led to the hypothesis that the 
immunopathology of tuberculous ECP is largely driven by a pathological cross-regulatory 
and fibrotic response which abrogates the protective IFN-γ response, with consequent 
structural changes in the visceral pericardium which are manifested by constrictive 
physiology. No association has be found between IL-10 and TGF-β and CD4 count in HIV 
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infected persons,28suggesting that we should witness the same degree of visceral and parietal 
inflammation andfibrosis in both HIV infected and uninfected persons. Indeed, there was no 
difference in degree of pericardial fibrosis detected by CMR in both HIV infected and 
uninfected persons in this study 
Dyspnea was much more frequently present in HIV-infected persons in our study. Prior 
studies have also reported that HIV infected TBPC patients tend to present with greater 
degrees of dyspnea,22,23whichmay likely be related to greater myocardial involvement. 
However, breathlessness in this group of patients may indicate pulmonary tuberculosis, other 
opportunistic infections, diastolic dysfunction and heart failure from non-tuberculous related 
factors.  
In this study, we were unable to demonstrate active myocardial inflammation in patients. 
While the myocardial STIR SI ratio was higher in patients with HIV infection, this failed to 
reach statistical significance. Further, the levels of CK-MB and cardiac Troponin T, when 
measured, were not elevated. However, nodular tuberculous myocarditis detected on CMR 
that resolved following anti-tuberculous therapy has been described previously.19 
Determinants of LV systolic function in TBPC included heart rate, LV size, E/A ratio, 
pericardial LGE and pericardial thickness. It has been shown that in patients with HIV 
associated cardiomyopathy the presence LV systolic dysfunction is associated with a high 
mortality.29Interestingly, the presence of myocardial LGE was not associated with LV 
function in this study. The presence of myocardial LGE has been shown to portend a poor 
prognosis in many different clinical contexts.30-33Similarly, there is a high mortality 
associated with co-existence of HIV infection andtuberculous pericarditis. The overall 
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mortality rate at 6 months is 26%; 40% in patients with clinical HIV disease and 17% in 
those without.5Predictors of mortality in HIV-associated TBPC included a proven non-
tuberculous diagnosis, presence of clinical features of HIV infection, pulmonary tuberculosis 
(hence a greater burden of disease), and increasing age. There was also a trend towards an 
increase in mortality in patients with haemodynamic instability.4 
This study had several limitations. First, no patients without TBPC were included for 
comparison. Second, the vast majority of patients did not have serum biomarkers for CK-MB 
or cardiac troponins for assessment of acute myocardial injury. Third, no parametric mapping 
was performed in this cohort of patients. However, despite these limitations, in the largest 
CMR study of TBPC to date, we show that HIV infection is associated with increased 
myocardial fibrosis in TBPC.  
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Conclusions 
We utilised amultiparametric CMR approach to investigate the myocardial phenotype of 
TBPC patients. We observed evidence of increased myocardial fibrosis in patients with HIV. 
Also, there was increased pericardial thickness with associated pericardial enhancement on 
LGE CMR. Moreover, HIV infected TBPC patients were younger, had lower serum 
haemoglobin and were more likely to have NYHA class III and IV symptoms. Determinants 
of LV systolic function in TBPC on univariate analysis included heart rate, LV size, E/A 
ratio, pericardial LGE and pericardial thickness.  
We hypothesise that myocardial inflammation in HIV and tuberculous infection is the cause 
of increased myocardial fibrosis in our study participants. We were unable to assess causation 
and the direct contribution of HIV and tuberculous infections to this myocardial fibrotic 
process in this cross-sectional study. In the future, it will be important to assess the 
prognostic significance of these findings and to investigate therapeutic strategies that may 
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